title: Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
abstract: OBJECTIVE
  Tumors with p53 overexpression have been associated with enhanced resistance to cisplatin-based chemotherapy in a few and small studies involving non-small cell lung cancer. The relationships and interactions between p53, Rb and bcl-2 immunostaining, clinical parameters and response to cisplatin-based chemotherapy were evaluated in the present study.
  
  
  METHODS
  Histological specimens obtained by bronchial or fine-needle biopsy from patients who underwent cisplatin-based chemotherapy between 1992 and 1999 were evaluated by immunostaining.
  
  
  RESULTS
  There were 102 patients, 88 men. Median age was 63 years; 47 had stage III and 55 stage IV disease. Forty-six tumor samples (45%) had positive immunostaining for p53, 61 (59%) had negative immunostaining for Rb and 8 (8%) had positive immunostaining for bcl-2. The response rate of the group with p53 positive immunostaining was 26% versus 57% of the p53 negative group (P=0.004). In multivariate analyses p53 positive immunostaining was identified as an independent predictive factor for resistance to cisplatin-based chemotherapy (P=0.006).
  
  
  CONCLUSIONS
  Our study confirmed an association of p53 immunostaining and response rate of patients treated with cisplatin-based chemotherapy.
authors.affiliation: Division of Medical Oncology, Policlinico Monteluce, Perugia, Italy. vgregorc@hotmail.com
authors.forename: Vanesa
authors.initials: V
authors.lastname: Gregorc
authors.forename: Vienna
authors.initials: V
authors.lastname: Ludovini
authors.forename: Lorenza
authors.initials: L
authors.lastname: Pistola
authors.forename: Samir
authors.initials: S
authors.lastname: Darwish
authors.forename: Irene
authors.initials: I
authors.lastname: Floriani
authors.forename: Guido
authors.initials: G
authors.lastname: Bellezza
authors.forename: Angelo
authors.initials: A
authors.lastname: Sidoni
authors.forename: Antonio
authors.initials: A
authors.lastname: Cavaliere
authors.forename: Massimo
authors.initials: M
authors.lastname: Scheibel
authors.forename: Verena
authors.initials: V
authors.lastname: De Angelis
authors.forename: Emilio
authors.initials: E
authors.lastname: Bucciarelli
authors.forename: Maurizio
authors.initials: M
authors.lastname: Tonato
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002945:Cisplatin / Q000494:pharmacology* / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D016160:Retinoblastoma Protein / Q000378:metabolism*; D012907:Smoking; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
chemical_list: D019253:Proto-Oncogene Proteins c-bcl-2; D016160:Retinoblastoma Protein; D016159:Tumor Suppressor Protein p53; D002945:Cisplatin